Medical Marijuana, Inc., the first publicly traded cannabis company in the United States, today announced that its major investment company AXIM Biotechnologies, Inc. has entered into a Clinical Study Agreement (CSA) with the University of British Columbia in Canada to begin a clinical trial with its CanChew Plus® cannabidiol (CBD) chewing gum product to treat drug-induced psychosis in adult patients.
The University will work with Health Canada and their own ethics board to design the trial, which will be conducted at the University of British Columbia, Canada, and will demonstrate the efficacy of AXIM’s chewing gum product composed of 50mg CBD to treat drug-related psychosis.
“We are proud to see AXIM Biotech embark on this new clinical trial with the University of British Columbia in Canada,” said Medical Marijuana Inc. CEO Dr. Stuart Titus. “Psychosis can last up to a few days, and is often characterized by hallucinations, delusions, memory loss and confusion. We look forward to learning how CBD may help treat this medical condition.”
Drug-related psychosis, also known as substance-induced psychotic disorder, is any psychotic episode that is related to the abuse of an intoxicant. According to the National Alliance on Mental Illness, about 3 in every 100 people will experience at least one episode of psychosis in their lifetimes.
The University of British Columbia is a global center for research and teaching, consistently ranked among the 40 best universities in the world, and top three in Canada.
